Back
 ABCR  Vol.6 No.4 , October 2017
Clinicopathological and Immunohistochemical Features of Triple Negative Breast Cancer
Abstract: Objective: To investigate the clinicopathological and immunohistochemical features of triple-negative breast cancer. Methods: The clinicopathological and immunohistochemical data (Ki-67, CK5/6, EGFR, E-Ca, SAM, P53, P63, FAS) of 199 female patients who were treated for breast cancer in thyroid and breast surgery of Xiaogan Central Hospital from January 2015 to December 2016 was retrospectively analyzed by using spss22.0 statistical software and chi-square analysis. Results: Triple-negative breast cancer (replaced by TNBC below) and non-triple negative breast cancer (replaced by non TNBC below) in age, tumor size, lymph node metastasis, SAM, P53, P63 and FAS have no statistical difference (P > 0.05, see Table 1), while in WHO grade of invasive ductal carcinoma, KI-67, CK5/6, EGFR, E-Ca they have statistical differences (P < 0.05, see Table 1). The invasive ductal carcinoma WHO grade of TNBC is higher than that of non TNBC. It’s positive rate of Ki-67, CK5/6, EGFR (96.67%, 58.33%, 72.22%) and negative rate of E-Ca (68.18%) are higher than those of non TNBC (75.74%, 29.03%, 18.92%, 30.38%) (P < 0.05, see Table 1). Conclusions: The invasive ductal carcinoma WHO grade of TNBC is higher than that of non TNBC, while it’s Ki-67, CK5/6, EGFR positive rate and the negative rate of E-Ca are significantly higher than those of non TNBC. The immunohistochemical index above is expected to become potential targets for the treatment of TNBC.
Cite this paper: Chen, H. , Li, J. and Tan, W. (2017) Clinicopathological and Immunohistochemical Features of Triple Negative Breast Cancer. Advances in Breast Cancer Research, 6, 93-99. doi: 10.4236/abcr.2017.64008.
References

[1]   Zheng, L.H. and Liu, R. (2015) Contralateral Breast Cancer Risk Factors. Chinese Journal of Cancer, 37, 241-243.

[2]   Jiang, Z.F. (2015) Effect of Molecular Classification of Breast Cancer on Treatment. Chinese Journal of General Surgery (Electronic Version), 9, 12-15.

[3]   Zhang, H., Wang, W., Tian, T., et al. (2016) Expression and Significance of Ezrin in Triple Negative Breast Cancer. Journal of Xi'an Jiaotong University: Medical Science, 37, 574-577.

[4]   Goldhirsch, A., Winer, E.P., Coates, A.S., et al. (2013) Personalizing the Treatment of Women with Early Breast Cancer: Highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Annals of Oncology, 24, 2206-2223.
https://doi.org/10.1093/annonc/mdt303

[5]   Yuan, Y.W. (2015) The Latest Treatment and Research Progress of Triple Negative Breast Cancer. Chongqing Medical, 44, 2279-2282.

[6]   Tan, Q.Z. and Liu, D. (2014) Analysis of Clinicopathological Features and Prognostic Factors of Triple-Negative Breast Cancer and non-Tri-Negative Breast Cancer. Practical Journal of Cancer, 29, 1480-1482.

[7]   Yang, M., Dai, D.L., Cui, G.Z., Chen, L. and Ding, M.J. (2015) Clinical Pathological Classification and Pathological Features of Triple-Negative Breast Cancer and Non-Triple Negative. Modern Journal of Integrated Traditional Chinese and Western Medicine, 24, 2713-2715.

[8]   Shen, S.D., Chen, Z.R., Huang, Z., Xiao, G.F. and Lei, R.W. (2012) Expression and Significance of Ki67 in Different Molecular Types of Breast Cancer. The Practical Journal of Cancer, 27, 247-249.

[9]   Han, J.G., Jiang, Y.D., Zhang, G.H., et al. (2011) Clinicopathologic Characteristics and Prognosis of Young Patients with Breast Cancer. Breast, 20, 370-372.
https://doi.org/10.1016/j.breast.2011.02.011

[10]   Weigel, M.T. and Dowsett, M. (2010) Current and Emerging Biomarkers in Breast Cancer: Prognosis and Prediction. Endocrine-Related Cancer, 17, 245-262.
https://doi.org/10.1677/ERC-10-0136

[11]   Chen, N., Wang, H., et al. (2014) Expression of CK5/6 in Triple-Negative Breast Cancer. Journal of Modern Oncology, 22, 1334-1336.

[12]   Bertucct, F., Fineth, P., Cervera, N., et al. (2008) How Basal Are Triple-Negative Breast Cancers? International Journal of Cancer, 123, 236-240.
https://doi.org/10.1002/ijc.23518

[13]   Choi, J., Jung, W.H. and Koo, J.S. (2012) C1inicopathologic Features of Molecular Subtypes of Triple Negative Breast Cancer Based on Immunohistochemical Markers. Histology and Histopathology, 27, 1481.

[14]   Prak, H.S., Jang, M.H., Kim, E.J., et al. (2014) High EGFR Gene Copy Number Predicts Poor Outcome in Triple-Negative Breast Cancer. Modern Pathology, 27, 1212-1222.
https://doi.org/10.1038/modpathol.2013.251

[15]   Baselga, J., Gomez, P., Greil, R., et al. (2013) Randomized Phase II Study of the Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab with Cisplatin versus Cisplatin Alone in Patients with Metastatic Triple-Negative Breast Cancer. Journal of Clinical Oncology, 31, 2586-2592.
https://doi.org/10.1200/JCO.2012.46.2408

[16]   Liu, T., Shen, M., Wang, D., et al. (2014) Effects of Expression of MMP-9 and E-Cadherin in Triple-Negative Breast Cancer. Journal of Practical Oncology, 28, 19-23.

[17]   Yin, T., Chen, X., Yu, H., et al. (2009) Effects of VPA and SAHA on Apoptosis of Endometrial Carcinoma Cells and E-Cad Gene Expression. Chinese Journal of Clinical Oncology, 36, 1120-1124.

 
 
Top